

PERIODICAL ROOM  
HEALTH SCIENCES LIBRARY

# THE JOURNAL OF EXPERIMENTAL MEDICINE

HEALTH SCIENCES

*Edited by*

Anthony Cerami   Zanvil A. Cohn   Maclyn McCarty   Ralph Steinman

*Assistant Editors*


Allan R. Goldberg   Carl Nathan   Ellen Pure

*Advisory Editors*

Frederick W. Alt  
K. Frank Austen  
Baruj Benacerraf  
Constantin A. Bona  
Patrick Brennan  
George Cross  
John R. David  
Frank J. Dixon  
Bernard N. Fields  
Shu Man Fu  
Emil C. Gotschlich  
Alan N. Houghton  
Thomas J. Kindt  
Seymour J. Klebanoff  
Frank Lilly

Philippa Marrack  
Lloyd F. Mayer  
Hans J. Müller-Eberhard  
E. A. McCulloch  
Ralph L. Nachman  
Robert J. North  
Victor Nussenzweig  
Michael B. A. Oldstone  
William E. Paul  
Russell Ross  
Pablo Rubinstein

David H. Sachs  
Matthew D. Scharff  
Hans Schreiber  
Benjamin D. Schwartz  
Kendall A. Smith  
Jonathan Sprent  
Timothy A. Springer  
Alain Townsend  
Giorgio Trinchieri  
Zena Werb  
Alan F. Williams  
Darcy B. Wilson  
Henry J. Winn  
Samuel D. Wright



Published Monthly by The Rockefeller University Press

Volume 168, No. 3 September 1, 1988

UNIVERSITY OF MARYLAND  
OCT 2 1988  
LIBRARIES

**INFORMATION FOR CONTRIBUTORS** Send all contributions to the Editors of *The Journal of Experimental Medicine*, The Rockefeller University, Box 289, 1230 York Avenue, New York, New York 10021. Each manuscript is acknowledged by the Editors' office, and the author should notify the office if he does not receive acknowledgment within a reasonable time. Papers will be printed as soon as feasible after acceptance and, if possible, in the order in which they are received.

*Regular Contributions* should be limited to 20 printed pages including illustrations (approximately 40 typed pages, double-spaced). Articles that will be longer will be returned to the authors to be cut to the acceptable maximum. *Brief Definitive Reports* are accepted for rapid publication provided they represent complete, original studies that are documented by references, experimental procedures, and a summary. The reports must be limited to less than 6 standard Journal pages, or the manuscript will be returned to the authors.

Two copies of the manuscript should be submitted: (1) the original typescript, double-spaced – including references and legends, and (2) a fully legible carbon, mimeographed, or Xerox copy.

**PREPARATION OF MANUSCRIPT AND ILLUSTRATIONS** See inside back cover.

**PAGE CHARGES** A basic charge of \$30.00 is made for each page. An author's inability to honor page charges will not affect publication of acceptable articles.

**EXCESS PAGES OF PHOTOMICROGRAPHS** Four pages of photomicrographs can be included at the \$30.00 per page charge; a surcharge of \$100 will be made for each additional page.

**OFFPRINTS** Authors may purchase offprints of their articles at a cost indicated on the offprint order form that accompanies galley proof.

**INFORMATION FOR SUBSCRIBERS** The subscription price per year (two volumes, six issues each) is \$150, postal surcharge Europe only, \$40, and for a single number is \$12.50. Subscriptions, payable in advance, start with the first issue of the calendar year. Special student and intern rates available.

**MICROFORM** Subscriptions and back copies from Vol. 1 on, are available in microfiche and microfilm from University Microfilms, 300 North Zeeb Road, Ann Arbor, Michigan 48106.

*Inquiries* about subscriptions, back issues, and special student and intern rates should be addressed to the Order Service of The Rockefeller University Press, 222 East 70th Street, New York 10021.

*Remittances* should be made by check or money order payable to The Rockefeller University Press and addressed to Post Office Box 5108, Church Street Station, New York 10249. All checks *must* be drawn on U. S. banks.

*Claims* for nonreceipt of issues will be honored when received within 3 months of mailing for U.S.A. subscribers, 6 months for foreign subscribers.

*The Journal of Experimental Medicine* (ISSN 0022-1007) is published monthly for \$150 per year (postal surcharge Europe only, \$40 net) by The Rockefeller University Press, 222 East 70th Street, New York, NY 10021. Second-class postage paid at New York, NY and additional mailing offices. **POSTMASTER:** Send address changes to *The Journal of Experimental Medicine*, Order Service, The Rockefeller University Press, 222 East 70th Street, New York, NY 10021.

Copyright © 1988 by The Rockefeller University Press, 222 East 70th Street, New York, NY 10021.

Made in the United States of America.

The appearance of the code at the bottom of the first page of an article in this journal indicates that the Publisher gives consent for individual copies of that article to be made for personal or internal use. This consent is given on the condition, however, that – for

GLYCOSYLATION OF A V<sub>H</sub> RESIDUE OF  
A MONOCLONAL ANTIBODY AGAINST  $\alpha(1 \rightarrow 6)$  DEXTRAN  
INCREASES ITS AFFINITY FOR ANTIGEN

BY SUSAN C. WALLICK, ELVIN A. KABAT, AND SHERIE L. MORRISON

*From the Departments of Microbiology, Genetics and Development, and Neurology, and the Cancer/Institute for Cancer Research, Columbia University College of Physicians and Surgeons, New York, New York 10032*

Immunochemical characterization of antibodies against  $\alpha(1 \rightarrow 6)$  dextran has given insights into the size and shape of the antibody-combining site and the nature of the interaction between antibodies and antigen. We are now attempting to correlate the immunochemical properties of the antidextran antibodies with their primary structure. In the course of these studies cDNAs from three monoclonal anti- $\alpha(1 \rightarrow 6)$  dextran hybridoma cell lines, 14.6b.1, 5.54<sup>1</sup> and 19.22.1 (1, 2), were cloned, and the nucleotide sequences of their V<sub>H</sub> and V<sub>L</sub> regions were determined (3) (Table I). All synthesize an identical  $\kappa$  light chain with the V <sub>$\kappa$</sub> -OX1 germline gene (4) rearranged to the J <sub>$\kappa$</sub> 2 segment; the heavy chains differ by only one or two amino acids in their complementarity-determining regions (CDRs)<sup>2</sup>. When compared with 14.6b.1, 5.54 and 19.22.1 have an identical Thr  $\rightarrow$  Asn amino acid change at position 60 in V<sub>H</sub>; 5.54 has an additional change (Ser  $\rightarrow$  Gly) at position 31 in CDR1. The changes in heavy chain sequence result in 5.54 and 19.22.1 having a 10-fold or greater reduction in their binding constants for both polymeric dextran and isomaltoheptaose (IM7) when compared with 14.6b.1 (Table I).

The Thr  $\rightarrow$  Asn change in 5.54 and 19.22.1 leads to the loss of a potential N-linked glycosylation site (Asn<sub>58</sub>-Tyr<sub>59</sub>-Thr<sub>60</sub>) present in 14.6b.1. The purpose of this study was to determine whether this potential N-linked glycosylation site is used and if so, whether the addition of carbohydrate (CHO) to CDR2 affects the binding constant for dextran. It is difficult to demonstrate glycosylation of V<sub>H</sub> in the original hybridoma antibodies since both IgA and IgM isotypes are glycosylated within their C<sub>H</sub>1 domains and CHO present in Fd could be linked to either V<sub>H</sub> or C<sub>H</sub>. Therefore, we have transferred the three V<sub>H</sub> regions to the human IgG<sub>4</sub> constant region, which is devoid of CHO in its C<sub>H</sub>1 domain. In this report we demonstrate the presence of carbohydrate within the V<sub>H</sub> of 14.6b.1. Comparison of the association constants for aglycosylated tunicamycin (Tm)-treated and -untreated antibodies shows

This work was supported in part by grants AI-19042, CA-16858, CA-22736, and CA-13696 (to the Cancer Center) from the National Institutes of Health, and by grant DBM-860-0778 from the National Science Foundation. Address correspondence to Dr. Sherie L. Morrison, Department of Microbiology, 540 Molecular Biology Institute, University of California at Los Angeles, Los Angeles, CA 90024.

<sup>1</sup> The 5.54 mAb was designated as 5.54.4.24.1 by Newman and Kabat (2).

<sup>2</sup> Abbreviations used in this paper: CDR, complementarity-determining region; CHO, carbohydrate;

TABLE I  
*Immunochemical Properties of Hybridoma Antibodies Specific for Dextran B512*

Hybridoma	Mouse strain	Isotype	Site size	$K_a^{\dagger}$ <i>ml/g</i>	$K_{i,a}$ (IM7) <sup>‡,§</sup> <i>liter/mole</i>	Heavy Chain amino acid changes vs. 14.6b.1 prototype <sup>  </sup>		
						CDR1	CDR2	CDR3
14.6b.1 <sup>¶</sup>	BALB/c	IgA,k	6	$4.43 \times 10^5$	$5.76 \times 10^4$	—	—	—
5.54**	C57BL/6	IgA,k	6	$1.78 \times 10^4$	$3.02 \times 10^3$	31 Ser → Gly	60 Thr → Asn	—
19.22.1 <sup>¶</sup>	BALB/c	IgM,k	7	$8.87 \times 10^3$	$6.46 \times 10^3$	—	60 Thr → Asn	—

\* Maximum number of  $\alpha(1 \rightarrow 6)$ -linked glucose residues that fit the antibody combining site.

‡ Determined by affinity gel electrophoresis according to the method described by Takeo and Kabat (17).

§ Association constants of antidextran combining sites with isomaltoheptaose (IM7).

|| According to Akolkar et al. (3).

¶ According to Sharon et al. (1).

\*\* According to Newman et al. (2); designated as 5.54.4.24.1 by Newman et al.

These sequence data have been submitted to the EMBL/GenBank Data Libraries under accession number Y00809.

that the presence of CHO increases the  $aK_a$  of 14.6b.1 for dextran. The effect on binding is unique to the carbohydrate present in  $V_H$ , since absence of CHO from  $C_H2$  does not change the  $aK_a$  for dextran. Lastly, we have demonstrated that the CHO in  $V_H$  is more exposed than in  $CH_2$ .

### Materials and Methods

**Cell Lines.** 5.54 is a mouse hybridoma cell line synthesizing a C57BL/6 IgA,  $\kappa$  antibody specific for  $\alpha(1 \rightarrow 6)$  dextran. D3 is a spontaneous heavy chain-loss variant of 5.54 that synthesizes only the  $\kappa$  light chain characteristic of the antidextran hybridomas. The D3 light chain variant cell line was isolated by Dr. P. N. Akolkar (Columbia University, NY). Cell lines were grown in Iscove's Modified Dulbecco's medium (IMDM) (Gibco Laboratories, Grand Island, NY) supplemented with 3–5% FCS (Hyclone Laboratories, Logan, UT).

**Gene Transfection.** Gene transfection was by protoplast fusion using the method of Oi et al. (5) and modified as described by Tan et al. (6). Transfectant culture supernatants were tested for antibody production and dextran binding by ELISA (7). Dextran B512 was prepared from *Leuconostoc mesenteroides* strain B512 cultures by Dr. L. Matsuuchi as described (8). Horseradish peroxidase affinity purified goat anti-human IgG antibody was purchased from Sigma Chemical Co. (St. Louis, MO). D3 recipient transfected cells from positive wells were subcloned once in soft agarose (9), and clones that stained heaviest with rabbit anti-human IgG Fc antiserum (Cooper Biomedical, Inc., Malvern, PA) were chosen for further analysis.

**Biosynthetic Radiolabeling and Papain Digestion.** Transfectant cells were labeled in the presence of 15  $\mu$ Ci/ml of [ $^{35}$ S]Met or 100  $\mu$ Ci/ml D-[ $^{14}$ C]glucosamine hydrochloride as described (10).

Secretions from the cells were digested with papain (Sigma Chemical Co.) at 1:100 enzyme/protein ratio for 4 h at 37°C. The reaction was stopped by addition of iodoacetamide to 0.03 M. The Fc fraction and undigested antibody protein were precipitated by incubation with IgG-Sorb (Enzyme Center, Malden, MA). Fab was precipitated from the supernatant using rabbit anti-human Fab (prepared by Letitia A. Wims, Columbia University, NY) or by insolubilized dextran (Sephadex G75). Samples were reduced with 2-ME (0.15 M) and analyzed using 5% SDS-PAGE (5).

**Inhibition of Glycosylation.** Tm at a concentration of 8  $\mu$ g/ml (Boehringer Mannheim Biochemicals, Indianapolis, IN) was used to inhibit N-linked glycosylation. Cells were biosynthetically labeled for 3 h with [ $^{35}$ S]Met in the presence of Tm as described above. After pretreatment, secreted Ig in the culture supernatant was discarded, the cells were washed twice with IMDM, fresh Tm and [ $^{35}$ S]Met added, and treatment continued overnight at 37°C. Removal of CHO from Ig was verified by immunoprecipitation of the secreted antibody and analysis by SDS-PAGE.

**Determination of the Antibody Protein Concentration in Culture Supernatants.** Antibodies in culture supernatants diluted into BBS (0.02 M borate-buffered 0.75% saline, pH 8.3) were bound to polystyrene microtiter wells (Corning Glass Works, Corning, NY) for 3 h at 37°C. After blocking any unreacted sites with 1% BSA/PBS/0.05% Tween 20 for 1 h at room temperature, the ELISA plates were washed with PBS/0.05% Tween 20 three times, PBS once, and then bound Ig was quantitated by reaction with horseradish peroxidase-labeled anti-human IgG antibody and compared with a human IgG standard of known concentration. Assay results have been reproduced at least three times. Direct binding of antibody to microtiter plates was a more reproducible method than binding supernatants to plates sensitized with anti-human IgG antiserum, for reasons that are not clear.

**Determination of the Apparent Association Constants of Aglycosylated Con A-adsorbed or -untreated Transfectoma Antibody Against Dextran B512.** Apparent binding constants were determined using the method of Nieto et al. (11). In brief, the association constant for an antibody is defined as the reciprocal free ligand concentration necessary for occupying one half of the antibody-combining sites. If a fixed amount of antibody is reacted with an increasing amount of free ligand on a plate coated with antigen, the reciprocal of the free ligand concentration that causes 50% inhibition of binding to the plate is considered to be a function of the intrinsic  $K_a$  and is designated as the apparent affinity constant ( $aK_a$ ). The  $aK_a$  is calculated from the

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.